Posts

Preoperative administration of cannabidiol (CBD) in healthy dogs undergoing elective surgery in Colombia: 16 Cases

/by

. The objective of this study is retrospectively review the effect of a single dose administration of two pharmaceutical grade CBD oils on basic cardiorespiratory parameters and anesthetic recovery of dogs undergoing elective surgery. Complete medical and anesthesia records of healthy dogs of the spay/neuter program of Corporaciòn Universitaria Santa Rosa de Cabal UNISARC whose owners approved a preoperative single dose of CBD were included for analysis. Dogs were considered clinically healthy based on physical examination, complete hemogram and serum creatinine and ALT concentration

Read more

Cannabidiol A Race To Relief

/by

Authors: Nishi Whiteley and Ethan Russo, MD Published in HerbalGram 2020 Introduction Few chemical compounds have enjoyed such a rapid ascent to market acceptance and consumer popularity as CBD. According…

Read more

Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy

/by

Authors: Mathieu Kuchenbuch, Gianluca D’Onofrio, Nicole Chemaly, Giulia Barcia, Théo Teng, Rima Nabbout Published in Epilepsia Open July 2020 Abstract Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and…

Read more

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

/by

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019
—
Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Read more

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

/by

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018
—
Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

Read more

Cannabinoids in treatment-resistant epilepsy: A review.

/by

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017
—
Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

Read more

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

/by

Authors: Evan J. Hess, Kirsten A. Moody, Alexandra L. Geffrey, Sarah F. Pollack, et al
Epilepsia, October 2016
—
OBJECTIVE: Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients, 63% of whom develop treatment-resistant epilepsy. He…

Read more

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

/by

Authors: Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, et al
The Lancet Neurology, March 2016
—
BACKGROUND: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish w…

Read more

Cannabinoids and Epilepsy.

/by

Authors: Evan C. Rosenberg, Richard W. Tsien, Benjamin J. Whalley, Orrin Devinsky
Neurotherapeutics, October 2015
—
Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid syst…

Read more

Marijuana Use in Epilepsy: The Myth and the Reality.

/by

Authors: Kamil Detyniecki, Lawrence Hirsch
Current Neurology and Neuroscience Reports, October 2015
—
Marijuana has been utilized as a medicinal plant to treat a variety of conditions for nearly five millennia. Over the past few years, there has been an unprecedented interest in using cannabis extracts to treat epilepsy, spurred on by a few refractory pediatric cases featured…

Read more

Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.

/by

Authors: Dimah Saade, Charuta Joshi
Pediatric Neurology, May 2015
—
BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalog…

Read more

Phytocannabinoids and epilepsy

/by

Authors: R. G. dos Santos, J. E. C. Hallak, J. P. Leite, A. W. Zuardi, J. A. S. Crippa
Journal of Clinical Pharmacy and Therapeutics, April 2015
—
WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…

Read more